Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacoeconomic considerations in antiarrhythmic therapy.

P J Podrid1, R J Arnold, D J Kaniecki

  • 1Cardiac Arrhythmia Service, University Hospital, Boston, Massachusetts.

Pharmacoeconomics
|November 4, 1992
PubMed
Summary

The Cardiac Arrhythmia Suppression Trial (CAST) highlights risks of antiarrhythmic drugs. Comparing drug efficacy, side effects, and costs is crucial for treatment decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ventricular Tachycardia in the Young Athlete: A Systematic Approach to Selection of Drug Therapy.

The Physician and sportsmedicine·2016
Same author

Primary progressive aphasia: a tale of two syndromes and the rest.

Neurology·2012
Same author

Review of the development, validation, and application of predictive instruments in interventional cardiology.

Heart disease (Hagerstown, Md.)·2001
Same author

Use of a decision-analytic model to support the use of a new oral US contrast agent in patients with abdominal pain.

Academic radiology·2001
Same author

Proarrhythmia, a serious complication of antiarrhythmic drugs.

Current cardiology reports·2000
Same author

Improved calibration of time-of-flight mass spectra by simplex optimization of electrostatic ion calculations.

Analytical chemistry·2000

Area of Science:

  • Clinical Pharmacology
  • Cardiology
  • Health Economics

Background:

  • The Cardiac Arrhythmia Suppression Trial (CAST) has raised concerns regarding the safety of antiarrhythmic medications.
  • Adverse effects associated with antiarrhythmic therapies vary in severity and frequency.
  • Current understanding of comparative effectiveness and cost-effectiveness of these treatments is limited.

Purpose of the Study:

  • To evaluate the comparative efficacy of different antiarrhythmic agents.
  • To assess the incidence and costs associated with adverse effects of antiarrhythmic therapies.
  • To determine the cost-effectiveness of pharmacotherapy versus alternative treatment strategies for cardiac arrhythmias.

Main Methods:

  • Review of data from the Cardiac Arrhythmia Suppression Trial (CAST).
  • Analysis of efficacy, adverse event profiles, and treatment costs for various antiarrhythmic drugs.
  • Economic modeling to compare pharmacotherapy with other management approaches.

Main Results:

  • Uncertainty exists regarding the optimal initial choice of antiarrhythmic agent based on efficacy and safety.
  • The costs associated with managing adverse effects of these drugs are significant.
  • The cost-effectiveness of antiarrhythmic drug therapy compared to other strategies remains unclear.

Conclusions:

  • Further research is needed to guide the selection of antiarrhythmic drugs, considering a balance of efficacy, safety, and economic factors.
  • The findings underscore the complexity of managing cardiac arrhythmias and the need for comprehensive treatment evaluations.

Related Experiment Videos